Opko Health Inc (OPK)

[tomsylver]

Trans-Pacific Health Sciences Dialogue

Les Funtleyder, Director of Strategic Investments, OPKO Health


About

The Trans-Pacific Health Sciences Dialogue is a C-level meeting for biopharmaceutical industry executives who want to accelerate, explore and develop collaborations and partnerships with their counterparts in the most important Trans-Pacific health care markets including Japan, China, South Korea and North America.

Over the course of two days, executives, dealmakers, investors, professional advisors and KOLs with deep trans-pacific experience will share their insights and experiences in an intimate and collegial setting that encourages interaction and collaboration. The program features informative panel discussions and case studies that focus on best practices to create growth, achieve objectives, add value and minimize risk on both sides of the Pacific.

The Health Sciences Dialogue is a must-attend meeting for executives whose strategy includes establishing a Trans-Pacific collaboration or investment. Attendees will come away with a broad overview and insights that they simply will not get in other meetings.

Background

Now in its fourteenth year, the Health Sciences Dialogue was established to improve the productivity of partnerships between Asian and North American biopharmaceutical companies and their stakeholders. The event has developed a reputation as the best place for biopharma companies seeking to forge Trans-Pacific ventures to start exploring their options.

Organizers

The Trans-Pacific Health Sciences Dialogue is organized by Demy-Colton Life Science Advisors with the support of the Japan America Society of Greater Philadelphia

2014 Speakers

?Daniel D. Adams, Protein Sciences Corporation
?Jack M. Anthony, Founder, BioMentorz
?Paul Bolno, President and CEO, WaVe Life Sciences
?Pey Ni Chan, Managing Director, CMIC Asia-Pacific, Pte. Ltd.
?Helen Chen, Manager, L.E.K. Consulting Limited
?Peter B. Corr, Co-Founder and Managing General Partner, Auven Therapeutics
?Robert DeBenedetto, President & CEO, SFJ Pharmaceuticals, Inc.
?Yuan-Hua Ding, PhD, Executive Director, Head of External R&D Innovation – Asia/Pacific, Pfizer Worldwide Research & Development
?Iain D. Dukes, D. Phil., Senior Vice President, MRL Licensing & External Scientific Affairs, Merck
?Jamie Egan, Senior Vice President, Corporate Development, Anges-MG, Inc
?Jay N. Fastow, JD, Partner, Ballard Spahr
?David P. Flores, Co-Founder, President & CEO, BioCentury Publications Inc.
?James Foley, Managing Director, Aqua Partners
?Les Funtleyder, Director of Strategic Investments, OPKO Health
?John M. Gill, Co-Founder and former President & CEO (Former) of Tetralogic Pharmaceuticals
?Glen Giovannetti, Global Biotechnology Leader, EY, LLP
?Kimberly Ha, Senior Director, FTI Consulting
?Charles Hsu, PhD, Managing Partner, Crosswave Management
?Chizuko Koseki, Founder & Director, transB Ltd
?Kiyoshi Kurokawa, Professor, National Graduate Institute for Policy Studies & Science Advisor, National Diet, Japan
?Wei Li, PhD, Senior Associate, Fidelity Biosciences
?Anjiang (Vincent) Liu, Managing Director, International Investment & Chief Representative, NY Office, FosunPharma Group
?Grace L. Pan, Partner, Orrick, Herrington & Sutcliffe LLP
?Andrew L. Pecora, MD, Chief Innovations Officer and Professor & Vice President of Cancer Services, Hackensack University Medical Center
?Nathan (Nick) B. Pliam, MD, PhD, Scientist-in-Residence, Bay City Capital LLC
?Terence G. Porter, PhD, Vice President, Search & Evaluation, Global Business Development, Takeda Pharmaceuticals International, Inc.
?Byung-Geon Rhee, PhD, CEO and President, Green Cross Holdings
?Anthony Y. Sun, MD, Partner, Aisling Capital
?Goro Takeda, Venture Partner, Sofinnova Ventures
?Joseph Vacca, PhD, Senior Vice President, Early Success Sharing Partnerships, WuXi AppTec
?Gunther Winkler, PhD, Founder and CEO, Biometheus LLC
?Harold R. Werner, Co-Founder, HealthCare Ventures
?Alan Yan, Co-Founder, President & CEO, Beijing SynerCare Pharma Tech Co., Ltd.
?Peony Yu, MD, Vice President, Clinical Development, FibroGen, Inc.
?Wei Zhang, PhD, Head, Corporate Development, Good Start Genetics Inc

Les Funtleyder, BA, MPH
Les Funtleyder is a consulting partner to BlueCloud Healthcare and is responsible for the development and management of healthcare investment funds and related products. Les has been involved with the healthcare industry since 1993, both as a portfolio manager, analyst, and an employee of major pharmaceutical companies.
Les was until very recently a managing director of Poliwogg, a private equity healthcare firm.

Prior to Poliwogg, he was a portfolio manager and healthcare strategist for the Miller Tabak Healthcare Transformation Fund, managed a healthcare equity portfolio for Provident Advisors and a medical device analyst at UBS Warburg.

Les has written Healthare Investing: Profiting from the New World of Pharma, Biotech and HealthCare sevices (McGraw Hill) published in January 2009, which bridges the gap between health reform, innovation and investing.

He is widely quoted in the Wall Street Journal, the New York Times, and is a frequent guest on CNBC and Bloomberg.

He holds a Masters in Public Health from Columbia University and a BA from Tulane University.

Uncletlzz | July 25, 2014 at 11:59 pm | Tags: BA, BlueCloud Healthcare, Les Funtleyder, MPH, opko health, Trans-Pacific Health Sciences Dialogue | Categories: OPKO Health, Uncategorized, Video | URL: http://wp.me/p43fcR-vz